8009906473_81da7b8652_o.jpg
photo-1429277096327-11ee3b761c93.jpg
5825871567_c358eda18e_o.jpg
8009906473_81da7b8652_o.jpg

Intro


Research and Development of

Novel, First-In-Class Medications

for Human Health

 

Explore Technology

 

SCROLL DOWN

Intro


Research and Development of

Novel, First-In-Class Medications

for Human Health

 

Explore Technology

 

 

AccenGen Therapeutics, Inc. is an early-stage pharmaceutical company focused on developing products using soluble epoxide hydrolase (sEH) inhibitors (sEHI) and dual sEH/COX inhibitors for indications with fibrotic etiologies and highest unmet needs. Our highest priority indication is treating pulmonary fibrosis, a disease worse than many cancers.

sEH studies have resulted in over 800 publications in top-tier peer-reviewed journals.

 
photo-1429277096327-11ee3b761c93.jpg

Story


For something that touches us all.

Story


For something that touches us all.

5825871567_c358eda18e_o.jpg

Ride


sEH core technology platform allows multiple product opportunities and diversified risk.

Ride


sEH core technology platform allows multiple product opportunities and diversified risk.